STOCK TITAN

Sunshine Biopharma Inc. - SBFM STOCK NEWS

Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.

Sunshine Biopharma Inc (SBFM) is a pharmaceutical company based in Montreal, Quebec, Canada, offering a wide range of life-saving medicines in therapeutic areas such as oncology and antivirals. The company's proprietary drug development program includes K1.1 mRNA for liver cancer, SBFM-PL4 for SARS Coronavirus infections, and Adva-27a for pancreatic cancer. With two reportable segments, Generic Pharmaceuticals and Nonprescription Over-The-Counter Products, Sunshine Biopharma generates most of its revenue from the Generic Pharmaceuticals segment.

Rhea-AI Summary
Sunshine Biopharma Inc. has closed its private placement, raising approximately $5 million in gross proceeds. The company issued 5,952,381 units and pre-funded units at a purchase price of $0.84 per unit. Each unit or pre-funded unit includes one share of common stock and two non-tradable warrants. The warrants have a term of five and a half years. Aegis Capital Corp. acted as the Exclusive Placement Agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
69.81%
Tags
Rhea-AI Summary

Sunshine Biopharma (NASDAQ: SBFM) reported significant progress for the fiscal year ending December 31, 2022. Key highlights include a cash position of $21 million and a revenue surge from $228,426 in 2021 to $4,345,603 in 2022, largely due to the acquisition of Nora Pharma Inc., which added 49 prescription drugs to their portfolio. The company is advancing its proprietary drug development programs, collaborating with the University of Arizona on COVID-19 treatment and progressing the K1.1 mRNA anticancer initiative. Sunshine Biopharma plans to increase its offerings to 86 generic pharmaceuticals over the next two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
-
Rhea-AI Summary

Sunshine Biopharma (NASDAQ: SBFM) announced a worldwide exclusive license agreement with the University of Arizona for technology related to PLpro protease inhibitors targeting SARS-CoV-2. This collaboration, which began in February 2022, aims to enhance the fight against COVID-19 by providing an additional treatment option beyond existing therapies like Paxlovid®. The licensed technology includes small molecules that inhibit PLpro, essential for the virus's pathogenicity. The agreement marks a significant milestone in Sunshine Biopharma's COVID-19 treatment pipeline, which also includes various cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
covid-19
-
Rhea-AI Summary

Sunshine Biopharma announced a research agreement with Sir Mortimer B. Davis Jewish General Hospital to further develop its anticancer drug, Adva-27a. This compound has shown effectiveness against drug-resistant cancer cells from various cancers. Under Dr. Gerald Batist's guidance, the research aims to complete IND-enabling studies, with potential plans for a Phase I clinical trial. Sunshine Biopharma has also expanded its operations by acquiring Nora Pharma Inc., enhancing its generics portfolio significantly. The ongoing focus remains on innovative cancer treatments alongside a robust pipeline, including drugs for liver cancer and COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
Rhea-AI Summary

Sunshine Biopharma has announced a $2 million share repurchase program to enhance shareholder value. The program allows for the acquisition of common stock on the open market or through private negotiations, contingent on market conditions and regulatory compliance. As of September 30, 2022, the company reported approximately $40.5 million in cash and equivalents, with 22.6 million shares outstanding. CEO Dr. Steve Slilaty emphasized this program is a strategic move amid ongoing progress in their oncology and antiviral drug development pipeline, including a COVID-19 treatment collaboration with the University of Arizona.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.49%
Tags
buyback
-
Rhea-AI Summary

Sunshine Biopharma (NASDAQ: SBFM) recently shared a shareholder letter from CEO Dr. Steve Slilaty, highlighting significant milestones achieved in 2022. The company raised a total of $45.5 million through public and private offerings, enabling expansion in drug development. Key developments included advancements in mRNA-based cancer treatment and a collaboration with the University of Arizona for anti-Coronavirus treatments. Notably, Sunshine acquired Nora Pharma Inc., which offers over 50 generic drugs, enhancing its growth prospects. The company aims for profitability while continuing to invest in proprietary drug development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
-
Rhea-AI Summary

Sunshine Biopharma (NASDAQ: SBFM) announced a collaboration with a leading lipid nanoparticle (LNP) company to further develop its mRNA-based anticancer macromolecule, K1.1. The partnership aims to create two LNP formulations, K1.1a and K1.1b, to conduct in vivo studies on human cancer models. Previously, K1.1 has shown effectiveness against various cancer cell types without harming normal human cells. The success of these studies could expedite human clinical trials. Sunshine Biopharma also continues its work on other cancer therapies and a COVID-19 treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Rhea-AI Summary

Sunshine Biopharma (NASDAQ: SBFM) has announced the acquisition of all outstanding shares of Nora Pharma, a rapidly growing generic pharmaceuticals company in North America. The deal, valued at approximately $21.9 million USD (30 million CAD), was finalized immediately, making Nora a wholly owned subsidiary. This acquisition is expected to enhance Sunshine's revenue stream significantly and solidify its position in the generic prescription drugs market. Nora Pharma will continue operations under its own brand, leveraging Sunshine's resources for accelerated growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags

FAQ

What is the current stock price of Sunshine Biopharma (SBFM)?

The current stock price of Sunshine Biopharma (SBFM) is $3 as of December 23, 2024.

What is the market cap of Sunshine Biopharma (SBFM)?

The market cap of Sunshine Biopharma (SBFM) is approximately 5.4M.

Where is Sunshine Biopharma Inc based?

Sunshine Biopharma Inc (SBFM) is based in Montreal, Quebec, Canada, at 469 Jean-Talon West, 3rd floor.

What are the core therapeutic areas of focus for Sunshine Biopharma Inc?

Sunshine Biopharma Inc focuses on therapeutic areas such as oncology and antivirals, offering life-saving medicines in these fields.

What are the key segments of Sunshine Biopharma Inc's business?

The company has two reportable segments: Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products, with the majority of revenue coming from the Generic Pharmaceuticals segment.

What are the main components of Sunshine Biopharma Inc's drug development program?

Sunshine Biopharma Inc's drug development program includes K1.1 mRNA for liver cancer, SBFM-PL4 for SARS Coronavirus infections, and Adva-27a for pancreatic cancer.

How does Sunshine Biopharma Inc generate revenue?

Sunshine Biopharma Inc generates the majority of its revenue from the Generic Pharmaceuticals segment.

What was the recent financial activity of Sunshine Biopharma Inc?

Sunshine Biopharma Inc recently announced a $10.0 million public offering to support its operations and working capital, with the proceeds expected to be used for general corporate purposes.

What are some of the recent achievements of Sunshine Biopharma Inc?

Sunshine Biopharma Inc received approval from Health Canada for its Biosimilar product NIOPEG, a pegylated form of filgrastim, demonstrating the company's commitment to leadership in the pharmaceutical sector.

What is the outlook for Sunshine Biopharma Inc in terms of new product launches?

Sunshine Biopharma Inc plans to launch 32 additional drugs in Canada in 2024 and 2025, expanding its product offering and market presence.

How does Sunshine Biopharma Inc contribute to the cancer treatment landscape?

Sunshine Biopharma Inc's products like Adva-27a for pancreatic cancer and K1.1 mRNA for liver cancer aim to provide innovative solutions in cancer treatment.

What is the company's goal in terms of profitability?

Sunshine Biopharma Inc is diligently working towards achieving profitability while focusing on growth, expansion, and bringing life-saving drugs to market.

Sunshine Biopharma Inc.

Nasdaq:SBFM

SBFM Rankings

SBFM Stock Data

5.40M
1.99M
0.23%
1.84%
11.7%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
FORT LAUDERDALE